TMS Co., Ltd. (4891)

Overview

TMS Co., Ltd., founded in 2005 and based in Fuchu, Japan, operates in the pharmaceutical industry focusing on the research and development, manufacturing, and marketing of a wide range of healthcare products. These include drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is at the forefront of developing innovative treatments for a variety of conditions, with a particular emphasis on acute ischemic stroke and inflammatory complications. TMS Co., Ltd. is actively engaged in collaborations with prestigious universities and strategic alliances with industry partners to enhance its research capabilities and market reach.

Products and Services

TMS Co., Ltd. offers a diverse portfolio targeting various medical needs, highlighted by its developmental drug candidates:

• TMS-007: This is a leading drug candidate under development by TMS Co., Ltd. It is a Stachybotrys microspora triprenyl phenol (SMTP) congener designed with prothrombolytic and anti-inflammatory/antioxidative activities. TMS-007 has successfully completed Phase 2a clinical trials for the treatment of acute ischemic stroke, showing promise in improving patient outcomes after stroke events.
• TMS-008: Another SMTP congener, TMS-008 is in the nonclinical development stage and is being designed to address inflammatory complications. It targets conditions such as acute kidney injury and cancer cachexia through its anti-inflammatory/antioxidative properties. TMS-008 represents the company’s commitment to expanding its product pipeline into new therapeutic areas.
• TMS-009: Currently in preclinical development, TMS-009 is a product candidate that further signifies TMS Co., Ltd.'s exploration into novel therapeutic options. Specific details about its target indications and mechanism of action are part of the company's strategic research and development program.

In addition to its proprietary drug development programs, TMS Co., Ltd. fosters strong collaborative research initiatives. Notable collaborations include a partnership with Hokkaido University and Kanazawa University for evaluating novel drug compounds, and a joint research agreement with Teikyo University focused on identifying kidney function biomarkers. Furthermore, the strategic alliance with Ji Xing Pharmaceuticals Limited showcases TMS Co., Ltd.'s dedication to leveraging partnerships for accelerated drug development and commercialization.